Prognostic role of euthyroid sick syndrome in MIS-C: results from a single-center observational study.
COVID-19
SARS-CoV2
children
euthyroid sick syndrome
multisystem inflammatory syndrome
Journal
Frontiers in pediatrics
ISSN: 2296-2360
Titre abrégé: Front Pediatr
Pays: Switzerland
ID NLM: 101615492
Informations de publication
Date de publication:
2023
2023
Historique:
received:
04
05
2023
accepted:
17
07
2023
medline:
28
8
2023
pubmed:
28
8
2023
entrez:
28
8
2023
Statut:
epublish
Résumé
Euthyroid sick syndrome (ESS) is characterized by low serum levels of free triiodothyronine (fT3) with normal or low levels of thyroid stimulating hormone (TSH) and free thyroxine (fT4) and is reported in different acute clinical situations, such as sepsis, diabetic ketoacidosis and after cardiac surgery. Our aim was to evaluate the predicting role of ESS for disease severity in patients with Multisystem Inflammatory Syndrome in children (MIS-C). A single-centre observational study on consecutive patients with MIS-C. Before treatment clinical, and laboratory data were collected and, in a subset of patients, thyroid function tests were repeated 4 weeks later. Variables distribution was analyzed by Mann-Whitney Forty-two patients were included and 36 (85.7%) presented ESS. fT3 values were significantly lower in patients requiring intensive care, a strong direct correlation was shown between fT3 and Hb, platelet count and ejection fraction values. A significant inverse correlation was retrieved between fT3 levels and C-reactive protein, brain natriuretic peptide, IL-2 soluble receptor and S-100 protein. Subjects with severe myocardial depression (EF < 45%) had lower fT3 values than subjects with higher EF. The thyroid function tests spontaneously normalized in all subjects who repeated measurement 4 weeks after admission. ESS is a frequent and transient condition in acute phase of MIS-C. A severe reduction of fT3 must be considered as important prognostic factor for severe disease course, with subsequent relevant clinical impact in the management of these patients.
Sections du résumé
Background
UNASSIGNED
Euthyroid sick syndrome (ESS) is characterized by low serum levels of free triiodothyronine (fT3) with normal or low levels of thyroid stimulating hormone (TSH) and free thyroxine (fT4) and is reported in different acute clinical situations, such as sepsis, diabetic ketoacidosis and after cardiac surgery. Our aim was to evaluate the predicting role of ESS for disease severity in patients with Multisystem Inflammatory Syndrome in children (MIS-C).
Methods
UNASSIGNED
A single-centre observational study on consecutive patients with MIS-C. Before treatment clinical, and laboratory data were collected and, in a subset of patients, thyroid function tests were repeated 4 weeks later. Variables distribution was analyzed by Mann-Whitney
Results
UNASSIGNED
Forty-two patients were included and 36 (85.7%) presented ESS. fT3 values were significantly lower in patients requiring intensive care, a strong direct correlation was shown between fT3 and Hb, platelet count and ejection fraction values. A significant inverse correlation was retrieved between fT3 levels and C-reactive protein, brain natriuretic peptide, IL-2 soluble receptor and S-100 protein. Subjects with severe myocardial depression (EF < 45%) had lower fT3 values than subjects with higher EF. The thyroid function tests spontaneously normalized in all subjects who repeated measurement 4 weeks after admission.
Conclusion
UNASSIGNED
ESS is a frequent and transient condition in acute phase of MIS-C. A severe reduction of fT3 must be considered as important prognostic factor for severe disease course, with subsequent relevant clinical impact in the management of these patients.
Identifiants
pubmed: 37635797
doi: 10.3389/fped.2023.1217151
pmc: PMC10448823
doi:
Types de publication
Journal Article
Langues
eng
Pagination
1217151Informations de copyright
© 2023 Fastiggi, Meneghel, Gutierrez de Rubalcava Doblas, Vittadello, Tirelli, Zulian and Martini.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
J Endocrinol Invest. 2022 Jan;45(1):199-208
pubmed: 34312809
J Clin Endocrinol Metab. 2003 Jul;88(7):3202-11
pubmed: 12843166
Am J Med. 2005 Feb;118(2):132-6
pubmed: 15694896
Physiol Res. 2021 Apr 30;70(2):153-159
pubmed: 33992044
Curr Opin Rheumatol. 2023 Jan 1;35(1):6-16
pubmed: 36094472
Front Endocrinol (Lausanne). 2020 Oct 07;11:566439
pubmed: 33117282
Int J Environ Res Public Health. 2020 Sep 11;17(18):
pubmed: 32932954
J Thorac Cardiovasc Surg. 2004 May;127(5):1509-11
pubmed: 15116015
Endocrinology. 1996 Dec;137(12):5250-4
pubmed: 8940342
J Endocrinol. 1989 Jul;122(1):177-83
pubmed: 2788696
J Endocrinol. 2010 Apr;205(1):1-13
pubmed: 20016054
Endocrinology. 1995 Mar;136(3):881-8
pubmed: 7867596
Ann Rheum Dis. 2021 Jan;80(1):88-95
pubmed: 32978237
N Engl J Med. 2020 Jul 23;383(4):334-346
pubmed: 32598831
Eur J Clin Invest. 2011 Feb;41(2):212-20
pubmed: 20964678
J Clin Endocrinol Metab. 1990 Jun;70(6):1735-43
pubmed: 2112152
Curr Opin Endocrinol Diabetes Obes. 2019 Oct;26(5):241-249
pubmed: 31343421
J Clin Res Pediatr Endocrinol. 2022 Jun 30;14(4):402-408
pubmed: 35770945
J Clin Invest. 2008 Mar;118(3):975-83
pubmed: 18259611
J Pediatr Endocrinol Metab. 2004 Oct;17(10):1435-42
pubmed: 15526723
Rev Endocr Metab Disord. 2020 Dec;21(4):495-507
pubmed: 32643004
Int J Cardiol. 2013 Sep 20;168(1):300-5
pubmed: 23041000
BMJ Case Rep. 2020 Aug 25;13(8):
pubmed: 32843467
J Endocrinol. 1995 Sep;146(3):475-83
pubmed: 7595143
J Endocrinol Invest. 2021 May;44(5):1085-1090
pubmed: 33025553
J Endocrinol Invest. 2021 Aug;44(8):1597-1607
pubmed: 33320308
BMC Endocr Disord. 2021 Nov 15;21(1):228
pubmed: 34781943
J Clin Invest. 2000 Aug;106(3):393-402
pubmed: 10930442
Thyroid. 1991 Summer;1(3):235-40
pubmed: 1668616
Endocrinology. 2007 Oct;148(10):4786-92
pubmed: 17628010
Endocrinology. 2006 Sep;147(9):4419-29
pubmed: 16728495
Lancet Diabetes Endocrinol. 2020 Sep;8(9):739-741
pubmed: 32738929
Thyroid. 2014 Oct;24(10):1456-65
pubmed: 24845024
Endocrinology. 2004 Apr;145(4):1649-55
pubmed: 14684601
J Endocrinol. 1994 Nov;143(2):359-65
pubmed: 7829998
Lancet. 2020 Jun 6;395(10239):1771-1778
pubmed: 32410760
Eur J Endocrinol. 1998 Jun;138(6):603-14
pubmed: 9678522
Endocrinology. 2020 Sep 1;161(9):
pubmed: 32652001
Endocrinology. 2002 Jul;143(7):2812-5
pubmed: 12072417
J Clin Endocrinol Metab. 1985 Apr;60(4):666-72
pubmed: 2857729
Circulation. 2021 Jan 5;143(1):78-88
pubmed: 33166178
Infect Dis Poverty. 2020 Apr 28;9(1):45
pubmed: 32345362
Best Pract Res Clin Endocrinol Metab. 2011 Oct;25(5):745-57
pubmed: 21925075
Eur J Endocrinol. 2020 Oct;183(4):381-387
pubmed: 32698147
Acta Endocrinol (Copenh). 1992 Sep;127(3):220-5
pubmed: 1329418
J Clin Endocrinol Metab. 2001 Sep;86(9):4198-205
pubmed: 11549650
J Pediatr. 1989 Jan;114(1):59-62
pubmed: 2909708
Ann Endocrinol (Paris). 2020 Oct;81(5):507-510
pubmed: 32950466
Saudi Med J. 2015 Feb;36(2):243-7
pubmed: 25719594
J Clin Endocrinol Metab. 2009 Aug;94(8):2781-6
pubmed: 19491228
Clin Exp Med. 2020 Nov;20(4):493-506
pubmed: 32720223